Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis
Status:
Unknown status
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective study consisting in testing whether systematic use of aspirin is
beneficial for primary prevention of vascular access for hemodialysis attested by doppler
ultrasound exam. The investigators will study aspirin resistance in the population of
patients undergoing hemodialysis. The investigators will test sensibility of resistant
patients to aspirin dose escalation. PFA-100 is the biologic test used in this study to
define aspirin resistance.